

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

7 March 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Shanghai GeCell Therapeutics LLC.* (上海精繕生物科技有限責任公司) (“**Shanghai GeCell Therapeutics**”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the “**Company**” and, together with its subsidiaries/units, the “**Group**”, the same applies below) recently received the approval from the National Medical Products Administration of China for the clinical trial of GCK-01 Cell Injection (the “**Investigational New Drug**”) for the treatment of relapsed or chemotherapy resistant Follicular Lymphoma. Shanghai GeCell Therapeutics intends to commence the Phase I clinical trial of the Investigational New Drug in China (excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below) when the conditions are fulfilled.

II. Basic Information and Research Progress on the Investigational New Drug

The Investigational New Drug is a cell therapy drug independently developed by the Group, which belongs to innovative biological drugs under Category 1 and is intended to be combined with antibodies to treat various hematological and solid tumors.

Currently, the treatment option for relapsed or chemotherapy resistant Follicular Lymphoma is mainly Rituximab in combination with chemotherapy drugs. The

Investigational New Drug is the first allogenic NK cellular therapy drug approved for clinical trials in China for this indication.

As of January 2024, the Group has invested approximately RMB48.54 million (unaudited) in total in the research and development (“**R&D**”) of the Investigational New Drug at this stage.

As of the date of this announcement, no similar allogenic NK cell therapy drug has been approved for marketing worldwide.

III. Risk Warning

As required by the relevant laws and regulations in China, the Investigational New Drug is subject to undergo a series of clinical studies and be approved by the national drug review authority before it can be launched. There are certain risks in the R&D of new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of new drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

7 March 2024

*For identification purpose only